Inactive Instrument
Sector Human Genome Sciences
Stocks
US4449031081
Biotechnology & Medical Research
|
End-of-day quote
Nasdaq
|
||
| - USD | - |
|
| 26/07/12 | Actelion Ltd : Exclusive: Human Genome rejected Amgen's $7 billion bid in 2010: sources | RE |
| 16/07/12 | BioMarin Pharmaceutical Inc. : GSK clinches deal to buy Human Genome for $3 billion | RE |
Main competitors
| Change | 5-day change | 1-month change | 3-month change | YTD change | 1-year change | 3-year change | 5-year change | 10-year change | Capi.($) | ||
|---|---|---|---|---|---|---|---|---|---|---|---|
 | - | 0.00% | - | - | - | - | - | - | - | 0 | |
| -0.86% | -1.67% | +2.81% | +16.49% | +7.47% | +1.23% | +18.22% | -25.42% | +210.09% | 50.47B | |
| -2.18% | -4.27% | +8.01% | +23.74% | +154.29% | +412.38% | +496.25% | +596.27% | - | 44.56B | |
| -1.07% | -0.36% | +10.34% | +38.80% | +15.04% | +41.13% | +16.48% | -0.16% | +235.46% | 43.08B | |
| -3.25% | -4.30% | +12.65% | +27.29% | +17.18% | +7.21% | +71.52% | +15.47% | +1,139.97% | 41.7B | |
| -0.31% | -0.83% | +0.37% | +3.80% | +10.63% | +19.47% | +48.24% | -20.29% | +156.02% | 33.21B | |
| -0.85% | -4.16% | +2.97% | +31.62% | +5.80% | +25.54% | +119.87% | +225.88% | +2,003.51% | 16.77B | |
| +6.21% | +3.87% | +7.29% | +19.60% | - | - | - | - | - | 16.28B | |
| -0.72% | -1.88% | +5.46% | +16.20% | +15.19% | +10.62% | +26.46% | -40.14% | +97.80% | 14.58B | |
| -0.99% | -3.04% | +24.51% | +59.00% | +45.13% | +79.53% | +39.98% | -34.78% | +247.91% | 13.92B | |
| -0.21% | -2.17% | +3.76% | +22.95% | -6.87% | -4.57% | -34.71% | -33.65% | +121.01% | 13.12B | |
| -2.51% | -6.03% | +41.74% | +17.77% | +5.30% | -20.63% | - | - | - | 11.56B | |
| -0.01% | -0.07% | +0.35% | +42.43% | +23.01% | +35.42% | -7.73% | -42.03% | +174.67% | 11.35B | |
| -2.93% | -8.75% | +21.58% | +74.42% | +53.99% | +44.68% | +44.68% | -49.62% | - | 10.96B | |
| -0.41% | -1.17% | -8.80% | -13.28% | -19.48% | +43.84% | +454.00% | +209.25% | +2,323.75% | 10.58B | |
| +0.05% | +0.18% | +0.70% | +70.28% | +78.90% | +256.66% | +488.62% | - | - | 10.18B | |
| -1.75% | -2.97% | +16.27% | -20.14% | -23.91% | +4.71% | +49.48% | +51.40% | +103.02% | 10.15B | |
| -1.02% | -3.73% | +12.71% | +48.52% | +49.78% | +186.41% | +510.80% | +87.54% | - | 9.82B | |
| -3.26% | +3.86% | +87.60% | +178.16% | +172.79% | +91.09% | +84.33% | -8.31% | +1,454.13% | 9.77B | |
| -2.09% | -8.16% | +9.80% | +0.85% | +14.68% | +652.14% | +1,432.93% | +13.41% | - | 9.63B | |
| Average | -0.93% | -2.00% | +13.69% | +34.66% | +34.38% | +104.83% | +227.02% | +59.05% | +688.94% | 19.08B | |
| Weighted average by Cap. | -1.05% | -1.60% | +10.48% | +29.17% | +36.71% | +97.33% | +172.79% | +87.73% | +578.11% |
- Stock Market
- Stocks
- Stock
- Sector Human Genome Sciences
Select your edition
All financial news and data tailored to specific country editions
